Samantha Maragh

Summary

Affiliation: National Institute of Standards and Technology
Country: USA

Publications

  1. ncbi Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0
    John P Jakupciak
    Cipher Systems, Crofton, USA
    BMC Cancer 8:95. 2008
  2. ncbi Multiple strand displacement amplification of mitochondrial DNA from clinical samples
    Samantha Maragh
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Med Genet 9:7. 2008
  3. ncbi Performance of mitochondrial DNA mutations detecting early stage cancer
    John P Jakupciak
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Cancer 8:285. 2008
  4. ncbi Analysis of potential cancer biomarkers in mitochondrial DNA
    John P Jakupciak
    National Institute of Standards and Technology, Biochemical Science Division, Gaithersburg, MD 20899, USA
    Curr Opin Mol Ther 8:500-6. 2006
  5. ncbi Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer
    Yan Xiao
    Biochemical Science Division, Chemical Science and Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899 8311, USA
    Clin Chem 55:1307-15. 2009
  6. ncbi Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens
    Jennifer Maki
    Genesis Genomics, Thunder Bay, Canada
    Am J Clin Pathol 129:57-66. 2008
  7. ncbi Development of genomic reference materials for Huntington disease genetic testing
    Lisa Kalman
    Laboratory Practice Evaluation and Genomics Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Genet Med 9:719-23. 2007

Collaborators

Detail Information

Publications7

  1. ncbi Facile whole mitochondrial genome resequencing from nipple aspirate fluid using MitoChip v2.0
    John P Jakupciak
    Cipher Systems, Crofton, USA
    BMC Cancer 8:95. 2008
    ..0 (MCv2), and 4) assessing the somatic mtDNA mutation rate in benign breast diseases as a potential tool for monitoring early somatic mutations associated with breast cancer...
  2. ncbi Multiple strand displacement amplification of mitochondrial DNA from clinical samples
    Samantha Maragh
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Med Genet 9:7. 2008
    ..We applied the method to a small group of cancer cases and controls and demonstrated that WGA is capable of increasing the yield of starting DNA material with identical genetic sequence...
  3. ncbi Performance of mitochondrial DNA mutations detecting early stage cancer
    John P Jakupciak
    Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
    BMC Cancer 8:285. 2008
    ..The detection of mtDNA mutations in body fluids using resequencing microarrays, which are more sensitive than other sequencing methods, could provide a strategy to measure mutation loads in remote anatomical sites...
  4. ncbi Analysis of potential cancer biomarkers in mitochondrial DNA
    John P Jakupciak
    National Institute of Standards and Technology, Biochemical Science Division, Gaithersburg, MD 20899, USA
    Curr Opin Mol Ther 8:500-6. 2006
    ....
  5. ncbi Cell lines as candidate reference materials for quality control of ERBB2 amplification and expression assays in breast cancer
    Yan Xiao
    Biochemical Science Division, Chemical Science and Technology Laboratory, National Institute of Standards and Technology, Gaithersburg, MD 20899 8311, USA
    Clin Chem 55:1307-15. 2009
    ..A prior NIST workshop addressed this need by reaching a consensus to create cell lines as reference materials for HER2 testing...
  6. ncbi Mitochondrial genome deletion aids in the identification of false- and true-negative prostate needle core biopsy specimens
    Jennifer Maki
    Genesis Genomics, Thunder Bay, Canada
    Am J Clin Pathol 129:57-66. 2008
    ..In a blinded external validation study, the sensitivity and specificity were 83% and 79%, and the area under the ROC curve was 0.87. The 3.4 mtdelta may be useful in defining malignant, benign, and PTM prostate tissues...
  7. ncbi Development of genomic reference materials for Huntington disease genetic testing
    Lisa Kalman
    Laboratory Practice Evaluation and Genomics Branch, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA
    Genet Med 9:719-23. 2007
    ....